Feed SRRK
SR

Scholar Rock SRRK · NASDAQ

$39.90 -1.82% (-$0.74)

Market cap
$4.87B
Enterprise value
$4.64B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-88.8%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.62
Free float
82.7%

About the company

Scholar Rock Holding Corporation is a U.S.-based biotechnology company focused on developing therapeutics that specialize in innovative approaches to modulating biological signaling pathways. The company concentrates on developing drugs that target proteins and signaling molecules involved in cell growth and development, particularly in the fields of neurology, oncology, and immunology. Scholar Rock is positioned as a leader in highly targeted therapies with the potential to transform the treatment of a range of serious and previously difficult-to-treat diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

David L. Hallal

Employees

289

Headquarters

Cambridge

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.